Accelerate Diagnostics

134 articles about Accelerate Diagnostics

• Accelerate Diagnostics Reports Third Quarter 2021 Financial Results

  11/9/2021

  Accelerate Diagnostics, Inc. announced preliminary financial results for the third quarter for the period ended September 30, 2021, which remain subject to quarter end closing adjustments.

• Accelerate Diagnostics Schedules Call to Review 3rd Quarter 2021 Results

  10/19/2021

   Accelerate Diagnostics, Inc. announced today that management will host a conference call on Tuesday, November 9, 2021, at 4:30 p.m. Eastern Time to review 2021 third quarter financial results.

• Accelerate Diagnostics Announces Agreements to Exchange Approximately $51 Million in Principal Amount of Its 2.50% Convertible Senior Notes due 2023 for Common Stock

  9/23/2021

  Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 2.50% Convertible Senior Notes due 2023 (the "Notes").

• Accelerate Diagnostics Reports Second Quarter 2021 Financial Results

  8/5/2021

  Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2021.

• Accelerate Diagnostics Announces CE Mark and Availability in Europe of Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems

  8/3/2021

  Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the new IVD configuration of its Accelerate PhenoTest® BC kit has been CE marked and is ready for use in Europe.

• Accelerate Diagnostics Schedules Call to Review 2nd Quarter 2021 Results

  7/15/2021

  Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time to review 2021 second quarter financial results.

• Accelerate Diagnostics Launches a Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems in the United States

  7/7/2021

  Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the launch of a new IVD configuration of its Accelerate PhenoTest® BC kit in the United States.

• New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021

  6/30/2021

  Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) to be held July 9–12, 2021.

• Accelerate Diagnostics to Participate in William Blair 41st Annual Growth Stock Conference on June 3, 2021

  5/19/2021

   Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips , and Chief Financial Officer, Steve Reichling , will present virtually at the William Blair 41 st Annual Growth Stock Conference on Thursday, June 3, 2021 at 12:00 p.m. Central Time .

• Accelerate Diagnostics Reports First Quarter 2021 Financial Results

  5/6/2021

  Accelerate Diagnostics, Inc. announced financial results for the first quarter for the period ended March 31, 2021.

• Accelerate Diagnostics to Host Call to Review First Quarter 2021 Results

  5/5/2021

  Accelerate Diagnostics, Inc. announced that management will host a conference call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time to review 2021 first quarter financial results.

• Accelerate Diagnostics to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020, at 4:00 p.m. Eastern Time

  2/1/2021

   Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020 , at 4:00 p.m. Eastern Time .

• Accelerate Diagnostics schedules call to review 2020 fourth quarter and full year results

  2/1/2021

   Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Tuesday, February 23, 2021 , at 4:30 p.m. Eastern Time to review 2020 fourth quarter and full year financial results.

• Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results

  1/12/2021

  Accelerate Diagnostics, Inc. announced preliminary financial results for the fourth quarter and full year ending December 31, 2020.

• Accelerate Diagnostics Reports Third Quarter 2020 Financial Results

  11/5/2020

  Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2020.

• Accelerate Diagnostics Announces New FDA Clearance for Accelerate PhenoTest® Improvements

  9/16/2020

  Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the Company has received U.S. Food and Drug Administration (FDA) clearance for a new suite of product enhancements to the Accelerate Pheno® system, which improve performance and expand the system's antimicrobial susceptibility testing (AST) menu for bloodstream infections.

• Accelerate Diagnostics Announces FDA Emergency Use Authorization for COVID-19 Individual IgM and IgG Antibody Tests

  9/10/2020

  Accelerate Diagnostics, Inc. (NASDAQ:AXDX) and BioCheck, Inc., a privately-held San Francisco-based company focused on in vitro diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the individual BioCheck SARS-CoV-2 IgM Test Kit and the BioCheck SARS-CoV-2 IgG Test Kit.

• Accelerate Diagnostics Names Nedal Safwat Chief Strategy Officer

  8/24/2020

  Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that Nedal Safwat has been appointed Chief Strategy Officer

• Accelerate Diagnostics Announces FDA Emergency Use Authorization for COVID-19 Antibody Testing System

  8/18/2020

   Accelerate Diagnostics, Inc. (NASDAQ: AXDX) and BioCheck, Inc., a privately-held San Francisco -based company focused on  in vitro  diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fa

• Accelerate Diagnostics Reports Second Quarter 2020 Financial Results & Announces New Product Offering

  8/6/2020

  Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2020.